Open AccessPrimary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma
Author(s) -
Ross C. Laxton,
Sergey Popov,
Lawrence J. Doey,
Alexa Jury,
Ranjeev Bhangoo,
Richard Gullan,
Chris Chandler,
L. Brazil,
G. Sadler,
R. P. Beaney,
N. Sibtain,
Andrew King,
István Bódi,
Chris Jones,
K. Ashkan,
Safa AlSarraj
Publication year - 2013
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/not125
Subject(s) - isocitrate dehydrogenase , oligodendroglial tumor , idh1 , loss of heterozygosity , medicine , oncology , biology , methylation , methyltransferase , atrx , glioblastoma , hazard ratio , dna methylation , oligodendroglioma , pathology , cancer research , mutation , astrocytoma , genetics , gene , allele , confidence interval , enzyme , gene expression , biochemistry
Glioblastoma multiforme with an oligodendroglial component (GBMO) has been recognized in the World Health Organization classification-however, the diagnostic criteria, molecular biology, and clinical outcome of primary GBMO remain unclear. Our aim was to investigate whether primary GBMO is a distinct clinicopathological subgroup of GBM and to determine the relative frequency of prognostic markers such as loss of heterozygosity (LOH) on 1p and/or 19q, O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom